Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL)

This study is testing a special type of immune cell therapy called CAR T-cell therapy (using a product called CMD63) for children with a type of blood cancer called acute lymphoblastic leukemia (ALL) that has come back or stopped responding to treatment. The therapy involves taking immune cells from the patient, engineering them to attack the cancer, and infusing them back. **You may be eligible if...** - You are between 1 and 18 years old - You have ALL that has relapsed or did not respond to at least one prior treatment - Your cancer cells have a marker called CD19 - Your heart, liver, kidneys, and lungs are working adequately - Your parents or guardians (or you, if old enough) can give informed consent **You may NOT be eligible if...** - You have active graft-versus-host disease (a complication from a prior transplant) - You have another active cancer - You have an uncontrolled infection, heart failure, or severe psychiatric condition - You are pregnant or breastfeeding - You have HIV, active hepatitis B, or active hepatitis C Talk to your doctor to see if this trial is right for you.